Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth ; volume:40 ; number:1 ; day:13 ; month:9 ; year:2021 ; pages:1-14 ; date:12.2021
Journal of experimental & clinical cancer research ; 40, Heft 1 (13.9.2021), 1-14, 12.2021
- Creator
-
Doleschel, Dennis
Hoff, Sabine
Koletnik, Susanne
Rix, Anne
Zopf, Dieter
Kiessling, Fabian
Lederle, Wiltrud
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-021-02043-0
- URN
-
urn:nbn:de:101:1-2021112418472336169298
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Doleschel, Dennis
- Hoff, Sabine
- Koletnik, Susanne
- Rix, Anne
- Zopf, Dieter
- Kiessling, Fabian
- Lederle, Wiltrud
- SpringerLink (Online service)
Other Objects (12)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Regorafenib : kolorektales Karzinom: Behandlungsoption nach Standardtherapie
Regorafenib: Nutzenbewertung gemäß § 35a SGB V
Regorafenib: Addendum zum Auftrag A15-43
Addendum zum Auftrag A13-37 (Regorafenib)
Regorafenib - Nutzenbewertung gemäß § 35a SGB V
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Molecular Beam Epitaxial Regrowth of Antimonide-Based Semiconductors
Synthesis of Monodisperse Silica Particles by Controlled Regrowth
Factors affecting calcium oxalate dihydrate fragmented calculi regrowth
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Regorafenib : kolorektales Karzinom: Behandlungsoption nach Standardtherapie
Regorafenib: Nutzenbewertung gemäß § 35a SGB V
Regorafenib: Addendum zum Auftrag A15-43
Addendum zum Auftrag A13-37 (Regorafenib)
Regorafenib - Nutzenbewertung gemäß § 35a SGB V
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Molecular Beam Epitaxial Regrowth of Antimonide-Based Semiconductors
Synthesis of Monodisperse Silica Particles by Controlled Regrowth
Factors affecting calcium oxalate dihydrate fragmented calculi regrowth
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Regorafenib : kolorektales Karzinom: Behandlungsoption nach Standardtherapie
Regorafenib: Nutzenbewertung gemäß § 35a SGB V
Regorafenib: Addendum zum Auftrag A15-43
Addendum zum Auftrag A13-37 (Regorafenib)
Regorafenib - Nutzenbewertung gemäß § 35a SGB V
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Molecular Beam Epitaxial Regrowth of Antimonide-Based Semiconductors
Synthesis of Monodisperse Silica Particles by Controlled Regrowth